Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$5.13M+8.4%$4.73M+12.2%$4.22M+8.9%$3.87M+20.8%$3.21M-27.8%
$4.12M$2.86M
$9.25M+12.1%$8.26M+16.5%$7.08M+3.1%$6.87M+13.4%$6.06M-12.4%
-$9.25M-12.1%-$8.26M-16.5%-$7.08M-3.1%-$6.87M-13.4%-$6.06M+12.4%
$845K+41.5%$597K+104%$292K+7.4%$272K+8.8%$250K+38.1%
-$8.41M-9.8%-$7.66M-12.8%-$6.79M-2.9%-$6.6M-13.6%-$5.81M+13.7%
-$0.050.0%-$0.05+16.7%-$0.06+14.3%-$0.070.0%-$0.07+12.5%
-$9.25M-12.1%-$8.26M-16.5%-$7.08M-3.1%-$6.87M-13.4%-$6.06M+12.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is SELLAS Life Sciences Group, Inc. profitable?
SELLAS Life Sciences Group, Inc. is not currently profitable: it reported a net loss of $29.5M over the trailing twelve months, a -4130.1% net margin.
What are SELLAS Life Sciences Group, Inc.'s profit margins?
Gross margin is 90.0% and operating margin is -4195.0%, with a -4130.1% net margin.
What is SELLAS Life Sciences Group, Inc.'s earnings per share?
SELLAS Life Sciences Group, Inc.'s diluted EPS over the trailing twelve months is $-0.23.
Where does SELLAS Life Sciences Group, Inc.'s income statement data come from?
Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.